Is USANA Health Sciences, Inc. overvalued or undervalued?

As of 31 October 2025, the valuation grade for USANA Health Sciences, Inc. moved from fair to very expensive. The company appears overvalued based on its current financial metrics. The P/E ratio stands at 16, while the EV to EBITDA ratio is 4.61, and the Price to Book Value is 1.03. In comparison, peers like Chromadex Corp. have a P/E ratio of 39.82, and Nature's Sunshine Products, Inc. shows a P/E of 21.11, indicating that USANA's valuation is significantly lower than some competitors, yet still classified as very expensive.
The stock has underperformed relative to the S&P 500, with a year-to-date return of -41.07% compared to the index's 16.30%, and a three-year return of -59.72% versus 76.66% for the S&P 500. This stark contrast in performance further reinforces the notion that USANA Health Sciences, Inc. is currently overvalued.